Three drug companies—Boehringer Ingelheim, AstraZeneca, and Novo Nordisk—allege that guidance on the Medicare Drug Price Negotiation Program issued by the Centers for Medicare and Medicaid Services ...
In his first month as president, Donald Trump and his administration have gleefully dismantled many of former President Joe Biden’s initiatives. However, there has been one notable exception: the ...
As many have now heard, on Thursday, August 15, 2024, the Centers for Medicare & Medicaid Services (CMS) released the prices for the first 10 prescription drugs selected for negotiation with ...
The new guidance builds on previous years’ by increasing the focus on transparency and expanding, per statute, to include details about how Medicare Part B drugs and renegotiation processes will be ...
“While we support affordable health care, the price controls that we are challenging would reduce access to new medicines that Americans are counting on, and would set a devastating precedent for all ...
“The Program cannot qualify as a physical taking under the Takings Clause because it does not ‘compel the surrender’ of property, or impose any ‘physical invasion or restraint upon’ it, and the owner ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results